Neuroone Medical Technologies (NMTC) Net Income towards Common Stockholders (2010 - 2026)

Neuroone Medical Technologies (NMTC) has reported Net Income towards Common Stockholders for 17 consecutive years, with -$2.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Income towards Common Stockholders fell 33.68% year-over-year to -$2.0 million; the trailing twelve-month figure through Jun 2026 stood at -$7.4 million (down 39.51% YoY), and the FY2025 full-year result was -$3.6 million, up 70.73% from the prior year.
• Net Income towards Common Stockholders grew to -$2.0 million in Q2 2026 per NMTC's latest filing, from -$2.4 million in the prior quarter.
• Across five years, Net Income towards Common Stockholders topped out at $1.8 million in Q4 2024 and bottomed at -$3.5 million in Q1 2023.
• Historically, Net Income towards Common Stockholders has averaged -$2.3 million across 5 years, with a median of -$2.6 million in 2022.
• The sharpest annual moves came in 2024 and 2025: Net Income towards Common Stockholders soared 153.37% in 2024, then slumped 180.54% in 2025.
• Over 5 years, Net Income towards Common Stockholders stood at -$1.7 million in 2022, then plunged by 93.04% to -$3.3 million in 2023, then jumped by 153.37% to $1.8 million in 2024, then tumbled by 180.54% to -$1.4 million in 2025, then slumped by 39.53% to -$2.0 million in 2026.
• According to Business Quant data, Net Income towards Common Stockholders over the past three periods registered -$2.0 million, -$2.4 million, and -$1.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.